Background: Cervical cancer screening guidelines have evolved significantly in the last decade for young adult women, with current recommendations promoting later initiation and longer intervals.
Introduction
During the last 6 decades, reductions in cervical cancer incidence and mortality have been achieved, due to integration of cytology into women's preventive healthcare (1, 2) , and increased understanding that cervical cancer is caused by persistent infection with human papillomavirus (HPV; refs. [3] [4] [5] [6] . HPV is the most common sexually transmitted infection, with peak prevalence among females ages 14-24 years (7) . Persistent HPV infections occur within a few years of first sexual intercourse (8) but can take years to develop into invasive cervical cancer (9) (10) (11) . Although the prevalence of HPV is greater among younger women than among women of older ages (7), cervical cancer incidence is very rare in women younger than 29 years of age (4, 12) because the majority of HPV infections are transitory and usually regress spontaneously within 2 years (9) .
Cervical cancer screening guidelines for average-risk women have evolved significantly over the last decade promoting later initiation and longer intervals. In 2000, guidelines recommended to begin screening at 18 years of age or at initiation of sexual activity (13) (14) (15) , with annual (14, 15) to triennial (13) intervals. By 2003, the U.S. Preventive Services Task Force issued recommendations and rationale for later starting age and triennial screening intervals (16) . In November 2012, concurrence across organizations was achieved; average-risk women should avoid screening before 21 years of age, with triennial screening intervals until 65 years of age (17) (18) (19) .
Guidelines that promote recommendations for less intervention can be difficult for physicians and the public to understand and support (20) . However, as screening increases, so do false-positive test results and colposcopies, with more false-positive test results occurring in women aged younger than 21 years (21) . Consequent unnecessary procedures conducted for treatment of preinvasive lesions that would regress or were falsely identified may have adverse reproductive and pregnancy outcomes (22) are especially salient for younger adult women who anticipate future pregnancy. In addition, screening women aged younger than 21 years, and all women annually can cause undue patient anxiety (23, 24) and costs to both patients and the healthcare infrastructure (25) (26) (27) .
By adhering to evidence-based guidelines, clinicians can minimize the physical, emotional, and financial costs of overscreening and overtreatment (20, 22, (28) (29) (30) . A national baseline of cervical cancer screening among young adult women before the 2012 screening guidelines update is necessary to measure implementation of current evidence-based guidelines for screening onset and frequency. To meet this need, national survey data from 2000-2010 were analyzed to estimate the prevalence of cervical cancer screening among women ages 18-29 years in the United States, focusing on these ages because of the distinction made in screening initiation and test recommendations on the basis of patient age.
Materials and Methods

Study population
The National Health Interview Survey (NHIS) is an annual survey of the civilian, noninstitutionalized U.S. population, conducted by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). Using multistage cluster sample design, a representative sample of households is selected for participation, and a personal household interview is conducted by U.S. Census Bureau interviewers according to procedures specified by NCHS. CDC's Division of Cancer Prevention and Control and National Cancer Institute's Division of Cancer Control and Population Sciences sponsor the Cancer Control Supplement of NHIS. Analyses that use public-use data do not require CDC Institutional Review Board approval.
NHIS collects self-reported information about Papanicolaou (Pap) test use from a randomly selected adult participant through the adult core and supplemental cancer control modules. Two distinct study samples based on survey data years were used for analysis. For the trend analysis (years 2000, 2005, 2008 , and 2010), the study sample was restricted to women ages 18-29 years who reported never having a hysterectomy and ever having a Pap test (n ¼ 11,248 
Correlates
Self-reported sociodemographic variables, namely age, race/ethnicity, educational attainment, poverty level (imputed income data), marital status, healthcare coverage (public, private, or none), and access to usual source of healthcare (a place other than emergency room where routine care is sought), were analyzed in relation to cervical cancer screening outcome measures. To adjust for their potential impact on age of initiation and frequency of Pap testing, awareness of HPV, HPV vaccine status, having ever given birth to a live born infant (increased visits with a provider, and Pap testing may occur during antepartum care), current birth control use (pills, implants, shots), and whether a physician recommended the most recent Pap test were included in the model.
Statistical analysis
NHIS has a complex survey design involving stratification, clustering, and disproportionate sampling. For the 2010 analysis of women who have ever had a Pap test, examining age at first Pap test by sociodemographic variables, the mean, median, and range, and 95% confidence intervals (CI) were reported. The difference between mean age for all covariates was tested using the t test for mean and corresponding P values were noted. For the univariable analysis of time since most recent Pap test, weighted proportions with 95% CIs were reported. Association between last reported screening and sociodemographic variables was assessed using c 2 statistics. To better understand the determinants of a more frequent interval for average-risk women ages 18-29 years, potential predictors of having a Pap test in the previous 12 months using multivariable logistic regression model were examined. To construct the multivariable model, a univariable analysis comparing last Pap test reported within 12 versus 13-36 months (data not shown) was conducted. Only statistically significant variables with P < 0.05 were included in the multivariable models. Associations were assessed with Wald-F statistics and differences among the age groups were tested using linear contrast and footnoted as significant. In addition, estimates based on 30 or fewer sample cases are considered to be unreliable and were suppressed and footnoted in the tables when necessary.
Results
Pap test trends among women ages 18-29 years, 2000-2010
Pap test trends for all ages combined reporting ever having a Pap test from 2000-2010 were not significant (P ¼ 0.243). However, the percentage of 18-year-old women who ever had a Pap test significantly decreased from 
Participant demographics, 2010
The 2010 study sample comprised mostly of non-Hispanic white (63.4%) women between the ages of 22-29 years (76.6%), who reported completing at least some college (39.7%), were living <200% above the federal poverty level (55.2%), never been married (48.2%), or were married/living with a partner (48.0%). Many were enrolled in a private health insurance plan (32.0%), reported a usual source of healthcare (79.0%), reported awareness of HPV (82.6%), or reported never receiving the HPV vaccine (81.4%). Most had never given birth to a live born infant (55.7%), and less than half were currently using non-barrier birth control (41.3%). Most reported having received a physician recommendation for their most recent Pap test (54.0%; Table 1 ).
Age at first Pap test, 2010
Reported mean age at first Pap test was significantly younger for 18-year-olds (15.9 years; P < 0.001) compared with women ages 19-29 years. Mean age at first Pap test was significantly younger for non-Hispanic blacks (16.9 years; P < 0.001), and older for Hispanics (18.1 years; P < 0.001) and Asians (19.8 years; P < 0.001) compared with non-Hispanic whites (17.4 years). Mean age at first Pap test was significantly younger for those with <high school education (16.9 years) compared with those with a college degree or greater (18.5 years; P < 0.001), for those reporting HPV vaccination (17.1 years; P 0.002), and having ever given birth (17.3 years; P < 0.001; Table 2 ). Among women ages 18-29 years who reported receiving the HPV vaccine, 20.6% (n ¼ 80) also reported a history of an abnormal Pap test in the previous 3 years (data not shown). Age of participant 
Time since most recent Pap test and predictors of last Pap test within 12 months, 2010
Most women ages 18-29 years reported their last Pap test was within the previous 12 months (73.1%; 95% CI, 70.4%-75.6%); few reported last Pap test within the previous 2 to 3 years (7.6%; 95% CI, 6.3%-9.2%). Usual source of healthcare (P < 0.001) and current birth control use (P < 0.001) were significantly associated with screening frequency (Table 3) . Multivariable regression modeling to examine the odds of reporting a Pap test during the previous 12 months, compared with greater than 12 months found that current use of birth control (P < 0.001; OR, 2.31; 95% CI, 1.74%-3.06%) and usual source of healthcare (P ¼ 0.002; OR, 1.64; 95% CI, 1.20%-2.25%) were significant (Table 4) .
Discussion
Because of how rare cervical cancer is among young women, and the harms associated with overscreening and treatment, national organizations are consistently recommending initiating cervical cancer screening at age 21 years, with longer intervals between screenings (17) (18) (19) . These data showed a significant continuing decline in Pap testing among 18-year-old women during 2000-2010. This may reflect early adoption of later screening initiation recommendations among women younger than 21 years of age (31) , possibly due to provider acceptance of, or the growing awareness among the public of the harms associated with premature screening and intervention. However, most young adult women reported screening within the previous 12 months, signaling the possibility of too-frequent Pap testing. Having a usual source of (Continued on the following column) NOTE: Includes all women who report ever having a Pap test, excludes women reporting hysterectomy, women who report an abnormal Pap in last 3 years, and women who reported their last Pap was not part of a regular screening exam. a Does not include responses "more than 3 years but not more than 5 years"; "over 5 years" because this study sample excludes women who reported an abnormal Pap in the last 3 years, thereby excluding women who report most recent Pap > 3 year ago. "Refused" and "don't know" excluded from analysis.
healthcare and current use of birth control methods requiring provider administration or provision (pills, implants, or shots) were strongly associated with the likelihood of having a Pap test in the previous year. Although fewer 18-year-olds reported ever receiving a Pap test in 2010, those who did had a younger age of initiation, compared with those ages 19-29 years who were surveyed. Upon further examination of the 18-year-olds who did report ever having a Pap test, 15.6% had a history of abnormal screening results (data not shown). Previous studies have shown greater Pap test use among women reporting risky sexual behaviors (32) , possibly explaining earlier Pap test initiation among these young women. Following younger users of the Pap test is important to understanding whether guidelines that discourage screening on the basis of sexual history are being implemented.
Non-Hispanic black women and women with less than a high school education reported a significantly younger age of Pap test initiation. Because 2010 was the first time data on age of first Pap test were collected on the NHIS, there is no previous screening initiation data available with which to compare these findings. Lower Pap testing rates have been documented among women with less education, Hispanic ethnicity, and shorter length of U.S. residency (33) (34) (35) (36) . Women who were vaccinated with the HPV vaccine also reported a younger age of first Pap test. Vaccine and Pap test receipt may be correlated, potentially indicating vaccination and screening in the same visit. In addition, age of first Pap test was younger for women who reported ever giving birth, as antepartum care increases visits with a provider and the potential for Pap testing.
The finding that most women reported their last Pap test within 12 months is not surprising. While at least onethird of the sample should report their last Pap test within the previous 12 months, even if all women were screened every 3 years, annual cervical cancer screening is commonly reported by young adult women (37) (38) (39) (40) and providers (41, 42) . Usual source of healthcare and current birth control use as significant variables impacting cervical cancer screening frequency has also been supported by previous research (36, 43, 44) . Pap tests and pelvic exams often are used as a prerequisite for birth control prescriptions, despite guidelines indicating they are unnecessary (45, 46) . The relationship between birth control use and Pap test receipt among young adults is significant, considering 36.6% of all women ages 18-29 years in the 2010 NHIS (data not shown) and 41.3% of this study sample report current birth control use. If the relationship between birth control use and Pap test receipt among younger adults is linked (38) , it would be important to discourage providers from offering Pap testing during visits for prescribing and administering contraception and to inform providers that an annual Pap test is not a necessary prerequisite to prescribe birth control through system-level intervention and incentive. We acknowledge several limitations with this study. While self-report is a common method used to assess Pap test utilization in national surveys, social desirability bias, recall bias, and overreporting of Pap test use possibly due to women equating any examination of the pelvic area with Pap test (43, (47) (48) (49) could potentially impact results. The number of women ages 18 and 19 years included in the 2010 study sample was small and should be noted. Because of the small percentage of women who reported HPV vaccination (18.6%), consistent with the lower uptake of the vaccine throughout the United States (50), the variable could not be further examined in this analysis. However, we believe it is crucial to provide baseline estimates of HPV vaccination for this age group, anticipating future analyses will have larger sample sizes to evaluate relationships. In addition, we were not able to control for screening in this age group that could occur in the context of prenatal and post-partum care (38) .
NHIS is the principal source of information on the health of the civilian noninstitutionalized population of the United States and provides self-reported screening rates to evaluate trends and determine whether collectively we are progressing toward meeting Healthy People 2020 objectives. This analysis presents an opportunity to nationally track screening behaviors among young adult women. It is significant because it is the first study using NHIS data to assess cervical cancer screening among women ages 18-29 year, and includes results from a novel NHIS question regarding age at initiation of cervical cancer screening. Studying this age cohort is important because of the distinct changes to screening guidelines that have occurred and the growing evidence base for less frequent intervention among young adult women.
Conclusions
Given the growing body of scientific evidence, women and clinicians should feel comfortable adopting later and less frequent intervention for cervical cancer detection among young adult women. As evidence-based screening guidelines gradually become more accepted among patients and providers, we anticipate continued decreases in the percentage of 18-year-old women reporting ever being screened and 18-to 29-year-old women reporting their last Pap test 12 months before survey. These anticipated changes signal research opportunities, including examining the characteristics and predictors of women who report their most recent Pap test 2 to 3 years before survey, and whether their reported interval was due to their provider implementing screening according to guidelines, or irregular healthcare access. In addition, understanding how the HPV vaccine and Pap test are used together in clinical practice will be of increasing public health significance as girls who were vaccinated become old enough for Pap testing. It will also be important to understand the content and delivery of cervical cancer screening guidance providers are offering to their patients after HPV vaccination. Continued unnecessary clinical services can lead to evaluation and treatment that generate physical, emotional, and financial costs. Implementation of evidence-based cervical cancer screening would increase the quality of cervical cancer prevention services for all women and reduce costs throughout society.
